UnknownNot applicableNCT04705389
SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines
Studying Cutaneous neuroendocrine carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University Hospital, Tours
- Principal Investigator
- Mahtab SAMIMI, MD-PhDUniversity Hospital, Tours
- Intervention
- Samples(other)
- Enrollment
- 150 enrolled
- Eligibility
- All sexes
- Timeline
- 2021 – 2023
Study locations (10)
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
- University Hospital of Helsinki, Finland, Helsinki, Finland
- Dermatology Dept, Hospital University of Tours, Tours, France
- Translational Skin Cancer Research, Essen, Germany
- National Tumour Institute "Fondazione G. Pascale" Unit of Melanoma - Cancer Immunotherapy and Innovative therapy, Naples, Italy
- Academic Hospital of Maastricht, Maastricht, Netherlands
- Department of Dermatology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
- Skin Cancer and Surgery Center, Sahlgrenska University Hospital, Gothenburg, Sweden
- Department of Dermatology, Başkent University Faculty of Medicine, Ankara, Turkey (Türkiye)
- Queen Elizabeth Hospital, Birmingham, United Kingdom
Collaborators
European Academy of Dermatology and Venerology
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04705389 on ClinicalTrials.govOther trials for Cutaneous neuroendocrine carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07302347A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT07288073TIL Therapy in cSCC and MCCKaram Khaddour, MD, MS
- RECRUITINGNCT07215988Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational StudyOhio State University Comprehensive Cancer Center
- RECRUITINGPHASE2, PHASE3NCT06947928Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell CarcinomaTuHURA Biosciences, Inc.
- RECRUITINGPHASE1NCT06940440IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)TuHURA Biosciences, Inc.
- RECRUITINGNCT06780475Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell CarcinomaAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE1NCT07080242Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine TumorsSystImmune Inc.
- RECRUITINGNCT06608511Liquid Biomarker Study in Melanoma and Non-Melanoma Skin CancersUniversity of Wisconsin, Madison